ESBATech News
Most Popular ESBATech Story
ESBATech rounds up $22M in second round
Switzerland's ESBATech has garnered $22 million in an extended Series B round. The money goes to expand its pipeline and advance the biotech's work developing antibody fragment therapies. SV Life... Read more...
Latest Headlines
- August 7, 2008
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
